

# Emanuela Scarpi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1067592/emanuela-scarpi-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

245  
papers

6,437  
citations

45  
h-index

70  
g-index

288  
ext. papers

7,353  
ext. citations

4.3  
avg, IF

5.15  
L-index

#	Paper	IF	Citations
245	Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel.. <i>BMC Medicine</i> , <b>2022</b> , 20, 48	11.4	0
244	Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab.. <i>Scientific Reports</i> , <b>2022</b> , 12, 3385	4.9	0
243	Development and Validation of the PaP Score Nomogram for Terminally Ill Cancer Patients. <i>Cancers</i> , <b>2022</b> , 14, 2510	6.6	0
242	Early Detection and Investigation of Extracellular Vesicles Biomarkers in Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , <b>2021</b> , 8, 732900	5.6	0
241	Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome. <i>Molecular Oncology</i> , <b>2021</b> , 16, 538	7.9	0
240	Patients with multiple myeloma referred for palliative care consultation: from retrospective analysis to future directions to improve clinical outcomes. <i>Supportive Care in Cancer</i> , <b>2021</b> , 1	3.9	1
239	Detection and Investigation of Extracellular Vesicles in Serum and Urine Supernatant of Prostate Cancer Patients. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	6
238	Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations. <i>Leukemia</i> , <b>2021</b> , 35, 2813-2826	10.7	3
237	Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 152-160	8.8	8
236	Early Gastric Cancer: identification of molecular markers able to distinguish submucosa-penetrating lesions with different prognosis. <i>Gastric Cancer</i> , <b>2021</b> , 24, 392-401	7.6	1
235	Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. <i>European Journal of Cancer</i> , <b>2021</b> , 152, 49-59	7.5	2
234	Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 716467	5.3	4
233	Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies. <i>Biomolecules</i> , <b>2021</b> , 11,	5.9	1
232	Prognostic Value of NLRP3 Inflammasome and TLR4 Expression in Breast Cancer Patients. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 705331	5.3	6
231	Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	1
230	The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a analysis of the IBIS 3 trial. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835919888999	5.4	3
229	Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	2

228	Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients. <i>Translational Oncology</i> , <b>2020</b> , 13, 186-192	4.9	6
227	The challenge of prognostication in palliative radiotherapy: the way forward is shared decision-making. <i>Supportive Care in Cancer</i> , <b>2020</b> , 28, 1545-1546	3.9	0
226	Prognostic role of a new index (multi inflammatory index) in patients with metastatic colorectal cancer: results from the randomized ITACa trial. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920958363	5.4	5
225	Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 982-987	8.7	12
224	Ga-PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage Radiotherapy. <i>Biomedicines</i> , <b>2020</b> , 8,	4.8	3
223	Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920937427	5.4	2
222	Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1325	5.3	6
221	Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study. <i>Scientific Reports</i> , <b>2020</b> , 10, 18190	4.9	4
220	Neoadjuvant treatment (FOLFOX4 plus hypofractionated tomotherapy) for patients with locally advanced rectal cancer: a multicenter phase II trial. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920977139	5.4	0
219	Intratumoral, rather than stromal, CD8+ T cells could be a potential negative prognostic marker in invasive breast cancer patients. <i>Translational Oncology</i> , <b>2019</b> , 12, 585-595	4.9	19
218	Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study. <i>Cancer Management and Research</i> , <b>2019</b> , 11, 4357-4369	3.6	10
217	Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , <b>2019</b> , 116, 158-168	7.5	23
216	Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. <i>Cancers</i> , <b>2019</b> , 11,	6.6	7
215	Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?. <i>Journal of Oncology</i> , <b>2019</b> , 2019, 1393505	4.5	3
214	Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis.. <i>JCO Precision Oncology</i> , <b>2019</b> , 3, 1-13	3.6	4
213	Role of SIRT-3, p-mTOR and HIF-1 $\alpha$ in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	16
212	Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer. <i>Journal of Visualized Experiments</i> , <b>2019</b> ,	1.6	1
211	Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2019</b> , 11, 1758835919866065	5.4	17

210	Independent Negative Prognostic Role of TCF1 Expression within the Wnt/ECatenin Signaling Pathway in Primary Breast Cancer Patients. <i>Cancers</i> , <b>2019</b> , 11,	6.6	6
209	Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide. <i>Prostate</i> , <b>2019</b> , 79, 1211-1220	4.2	14
208	Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up. <i>Radiation Oncology</i> , <b>2019</b> , 14, 112	4.2	7
207	Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3020-3020	2.2	3
206	Plasma AR status and cabazitaxel in heavily-treated metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 203-203	2.2	0
205	The prognostic role of progesterone receptor in patients with rapidly proliferating, hormone receptor-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 545-545	2.2	
204	Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5039-5039	2.2	0
203	Impact of physician experience and multidisciplinary team on clinical outcome in patients receiving sorafenib. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2019</b> , 43, e76-e78	2.4	4
202	Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 2425-2434	3.9	16
201	Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2019</b> , 75, 368-373	10.2	50
200	Association among metabolic syndrome, inflammation, and survival in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 240.e1-240.e11	2.8	13
199	An aggressive early gastric cancer: Kodama's PenA type. <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 1186-1190	3.6	4
198	Investigation of receptor radionuclide therapy with Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 923-930	8.8	38
197	Early Gastric Cancer: Clinical Behavior and Treatment Options. Results of an Italian Multicenter Study on Behalf of the Italian Gastric Cancer Research Group (GIRCG). <i>Oncologist</i> , <b>2018</b> , 23, 852-858	5.7	8
196	Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer. <i>European Radiology</i> , <b>2018</b> , 28, 2969-2978	8	12
195	Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?. <i>BMC Cancer</i> , <b>2018</b> , 18, 348	4.8	14
194	PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. <i>Scientific Reports</i> , <b>2018</b> , 8, 4254	4.9	78
193	Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24). <i>Targeted Oncology</i> , <b>2018</b> , 13, 469-479	5	23

192	Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?. <i>Frontiers in Endocrinology</i> , <b>2018</b> , 9, 137	5.7	10
191	Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	44
190	NHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2018</b> , 37, 96	12.8	13
189	Randomized, multicentre phase II trial of the sequencing of radium-223 and docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS396-TPS396	2.2	
188	Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 348-354	8.8	15
187	Re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. <i>Eur Urol</i> 2017;71:680-7. <i>European Urology</i> , <b>2018</b> , 73, e9-e10	10.2	1
186	IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab. <i>Cancer Management and Research</i> , <b>2018</b> , 10, 5659-5666	3.6	6
185	Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer. <i>BMC Cancer</i> , <b>2018</b> , 18, 1267	4.8	6
184	Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival. <i>OncoTargets and Therapy</i> , <b>2018</b> , 11, 6555-6567	4.4	20
183	Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. <i>Scientific Reports</i> , <b>2018</b> , 8, 15442	4.9	14
182	Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial. <i>OncoTargets and Therapy</i> , <b>2018</b> , 11, 5261-5268	4.4	5
181	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. <i>Tumori</i> , <b>2018</b> , 104, 476-479	1.7	12
180	Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 129, 44-53	7	15
179	Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?. <i>Translational Oncology</i> , <b>2018</b> , 11, 950-956	4.9	11
178	Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab. <i>Scientific Reports</i> , <b>2017</b> , 7, 1293	4.9	17
177	Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , <b>2017</b> , 77, 1012-1019	4.2	4
176	Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT). <i>Annals of Oncology</i> , <b>2017</b> , 28, 1910-1916	10.3	12
175	Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 1777-1778	8.8	1

174	Vitamin D receptor polymorphisms or serum levels as key drivers of breast cancer development? The question of the vitamin D pathway. <i>Oncotarget</i> , <b>2017</b> , 8, 13142-13156	3.3	18
173	DNA ploidy and S-phase fraction analysis in peritoneal carcinomatosis from ovarian cancer: correlation with clinical pathological factors and response to chemotherapy. <i>OncoTargets and Therapy</i> , <b>2017</b> , 10, 4657-4664	4.4	1
172	Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial. <i>Scientific Reports</i> , <b>2017</b> , 7, 10426	4.9	5
171	Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer. <i>Scientific Reports</i> , <b>2017</b> , 7, 15541	4.9	10
170	High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , <b>2017</b> , 21, 766-773	1.3	8
169	Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with Lu-D OTATATE. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 490-499	8.8	72
168	Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	31
167	Is androgen receptor useful to predict the efficacy of anti-estrogen therapy in advanced breast cancer?. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1042-1042	2.2	1
166	Efficacy of bevacizumab in second-line versus first-line treatment of metastatic colorectal cancer: Results from a new methodological approach based on the ITACa strategy trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3546-3546	2.2	1
165	Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 2423-2436	3.3	18
164	Vitamin D status among long-term survivors of testicular cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 36780-36786	3.3	10
163	NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients. <i>Oncotarget</i> , <b>2017</b> , 8, 65730-65742	3.3	11
162	Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC: A phase IV study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e20676-e20676	2.2	
161	Impact of admission to hospice on pain intensity and type of pain therapies administered. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 225-232	3.9	4
160	Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life. <i>European Journal of Cancer</i> , <b>2016</b> , 69, 110-118	7.5	80
159	Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 426-431	3.3	7
158	Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy. <i>Clinical Lung Cancer</i> , <b>2016</b> , 17, 384-390	4.9	60
157	Correlation of circulating tumor cells (CTCs) with peripheral blood leukocytes to predict outcome in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 11532-11532	2.2	1

156	Prognostic and predictive role of circulating eNOS and EPHB4 in metastatic colorectal cancer patients receiving bevacizumab.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e23083-e23083	2.2	1
155	Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. <i>Oncotarget</i> , <b>2016</b> , 7, 67142-67149	3.3	76
154	Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial. <i>Oncotarget</i> , <b>2016</b> , 7, 10193-202	3.3	14
153	Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. <i>Oncotarget</i> , <b>2016</b> , 7, 15243-51	3.3	25
152	eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. <i>Oncotarget</i> , <b>2016</b> , 7, 27988-99	3.3	26
151	Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 33210-9	3.3	98
150	Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions. <i>Oncotarget</i> , <b>2016</b> , 7, 40719-40724	3.3	4
149	Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 37839-37845	3.3	60
148	Systemic immune-inflammation index to predict the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 547-547	2.2	1
147	Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 231-231	2.2	
146	Circulating AR copy number and outcome to enzalutamide in patients with metastatic castration-resistant prostate cancer after docetaxel.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e16583-e16583	2.2	23
145	Salvage high-dose chemotherapy in female patients with relapsed/refractory germ cell tumors: The EBMT experience.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5558-5558	2.2	
144	Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. <i>Oncotarget</i> , <b>2016</b> , 7, 54564-54571	3.3	89
143	Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer. <i>PLoS ONE</i> , <b>2016</b> , 11, e0158952	3.7	39
142	Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer. <i>PLoS ONE</i> , <b>2016</b> , 11, e0167906	3.7	11
141	Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. <i>Frontiers in Pharmacology</i> , <b>2016</b> , 7, 376	5.6	93
140	No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC). <i>Scientific Reports</i> , <b>2016</b> , 6, 37621	4.9	5
139	Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer. <i>Molecular Diagnosis and Therapy</i> , <b>2016</b> , 20, 255-63	4.5	9

138	Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 1040-6	8.8	60
137	RANKL: A promising circulating marker for bone metastasis response. <i>Oncology Letters</i> , <b>2016</b> , 12, 2970-2975	7.5	20
136	Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial. <i>European Journal of Cancer</i> , <b>2016</b> , 65, 61-8	7.5	87
135	Expression of proteins involved in DNA damage response in familial and sporadic breast cancer patients. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 110-20	7.5	9
134	Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 159, 79-86	4.4	15
133	methylation and outcome of patients with advanced colorectal cancer treated with cetuximab. <i>Oncology Letters</i> , <b>2015</b> , 9, 1432-1438	2.6	3
132	Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 1874-81	7.5	13
131	Circulating tumor cells in early breast cancer: A connection with vascular invasion. <i>Cancer Letters</i> , <b>2015</b> , 367, 43-8	9.9	29
130	The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 1140-7	4.6	11
129	(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 1276-83	8.8	64
128	High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 1377-84	3.1	66
127	<sup>111</sup> In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: its accuracy and prognostic significance. <i>Nuclear Medicine Communications</i> , <b>2015</b> , 36, 135-42	1.6	1
126	Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 2719-25	4	51
125	Endobronchial/Endoesophageal Ultrasound (EBUS/EUS) Guided Fine Needle Aspiration (FNA) and <sup>18</sup> F-FDG PET/CT Scanning in Restaging of Locally Advanced Non-small Cell Lung Cancer (NSCLC) Treated with Chemo-radiotherapy: A Mono-institutional Pilot Experience. <i>Technology in Cancer Research and Treatment</i> , <b>2015</b> , 14, 721-7	2.7	8
124	Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. <i>PLoS ONE</i> , <b>2015</b> , 10, e0134732	3.7	25
123	Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis. <i>Clinical Lung Cancer</i> , <b>2015</b> , 16, e223-8	4.9	30
122	eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial. <i>Journal of Translational Medicine</i> , <b>2015</b> , 13, 258	8.5	23
121	High neutrophil to lymphocyte ratio (NLR) persistence during enzalutamide to predict poor clinical outcome in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e16059-e16059	2.2	2



120	HIF-1 alpha expression as a predictor of bevacizumab efficacy in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 601-601	2.2	2
119	Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colon rectal cancer: Results from the ITACa trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 617-617	2.2	1
118	Correlation between everolimus discontinuation or dose reduction induced by stomatitis or cutaneous toxicity and clinical outcome in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 448-448	2.2	
117	Effect of metformin on clinical outcome in advanced HCC patients receiving sorafenib.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15156-e15156	2.2	
116	Systemic immune-inflammation index (SII) as prognostic/predictive factor in patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15595-e15595	2.2	
115	eNOS polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15157-e15157	2.2	
114	Is Vit D serum concentration related to Italian and Tanzanian breast cancer cases?. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e22248-e22248	2.2	
113	Benefit from anthracyclines in relation to biological profiles in early breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 144, 307-18	4.4	18
112	Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2014</b> , 33, 65	12.8	12
111	177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2014</b> , 41, 1845-51	8.8	86
110	Improved stool DNA integrity method for early colorectal cancer diagnosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2014</b> , 23, 2553-60	4	11
109	KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC). <i>PLoS ONE</i> , <b>2014</b> , 9, e92071	3.7	43
108	CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen. <i>International Journal of Molecular Sciences</i> , <b>2014</b> , 15, 15767-77	6.3	18
107	New biomarkers to predict the evolution of in situ breast cancers. <i>BioMed Research International</i> , <b>2014</b> , 2014, 159765	3	8
106	Clinical and genetic factors related to cancer-induced bone pain and bone pain relief. <i>Oncologist</i> , <b>2014</b> , 19, 1276-83	5.7	8
105	Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response. <i>Journal of Translational Medicine</i> , <b>2014</b> , 12, 262	8.5	17
104	Palliative sedation for intolerable suffering. <i>Current Opinion in Oncology</i> , <b>2014</b> , 26, 389-94	4.2	18
103	Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. <i>Journal of Geriatric Oncology</i> , <b>2014</b> , 5, 156-63	3.6	21

102	Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, 182-9	3.3	18
101	Final outcome results of platinum-sensitive small cell lung cancer (SCLC) patients treated with platinum-based chemotherapy rechallenge: A multi-institutional retrospective analysis.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 7600-7600	2.2	1
100	High neutrophil to lymphocyte ratio persistent during first-line chemotherapy to predict clinical outcome in patients with advanced urothelial cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4540-4540	2.2	
99	RANKL circulating levels in the evaluation of bone response in breast cancer (BC) patients.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 11128-11128	2.2	
98	<sup>18</sup> F-fluorocholine positron emission tomography/computed tomography for early outcome prediction in metastatic castration-resistant prostate cancer patients treated with enzalutamide: A proof-of-principle study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e16040-e16040	2.2	
97	Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. <i>Journal of Translational Medicine</i> , <b>2013</b> , 11, 135	8.5	48
96	Role of <sup>18</sup> FDG PET/CT in patients treated with <sup>177</sup> Lu-DOTATATE for advanced differentiated neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2013</b> , 40, 881-8	8.8	100
95	Early gastric cancer: diagnosis, staging, and clinical impact. Evaluation of 530 patients. New elements for an updated definition and classification. <i>Gastric Cancer</i> , <b>2013</b> , 16, 549-54	7.6	39
94	Multicenter institutional experience of surgically resected thymic epithelial tumors (TETs): an observational report on behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone). <i>Annals of Surgical Oncology</i> , <b>2013</b> , 20, 2958-63	3.1	1
93	Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact. <i>Oncology</i> , <b>2013</b> , 84, 150-7	3.6	48
92	Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 1744-50	2.8	55
91	Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer. <i>Clinical Colorectal Cancer</i> , <b>2013</b> , 12, 122-7	3.8	19
90	Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC. <i>International Journal of Molecular Sciences</i> , <b>2013</b> , 14, 10332-42	6.3	64
89	RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study. <i>International Journal of Molecular Sciences</i> , <b>2013</b> , 14, 10683-93	6.3	12
88	Biology matters: the clinical impact of single-receptor discordance on breast cancer. <i>Annals of Oncology</i> , <b>2013</b> , 24, 851	10.3	1
87	MMP-7 and fcDNA serum levels in early NSCLC and idiopathic interstitial pneumonia: preliminary study. <i>International Journal of Molecular Sciences</i> , <b>2013</b> , 14, 24097-112	6.3	11
86	Palliative sedation in end-of-life care. <i>Current Opinion in Oncology</i> , <b>2013</b> , 25, 360-7	4.2	20
85	Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. <i>Heart</i> , <b>2013</b> , 99, 634-9	5.1	78

84	Body mass index and prognosis of metastatic breast cancer patients receiving first-line chemotherapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2013</b> , 22, 1862-7	4	17
83	Nuclear NHERF1 expression as a prognostic marker in breast cancer. <i>Cell Death and Disease</i> , <b>2013</b> , 4, e904	9.8	26
82	Multiple marker detection in peripheral blood for NSCLC diagnosis. <i>PLoS ONE</i> , <b>2013</b> , 8, e57401	3.7	48
81	Managing chronic pain: results from an open-label study using MC5-A Calmare <sup>®</sup> device. <i>Supportive Care in Cancer</i> , <b>2012</b> , 20, 405-12	3.9	31
80	Prospective observational Italian study on palliative sedation in two hospice settings: differences in casemixes and clinical care. <i>Supportive Care in Cancer</i> , <b>2012</b> , 20, 2829-36	3.9	27
79	Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. <i>Clinical Breast Cancer</i> , <b>2012</b> , 12, 264-9	3	67
78	Transbronchial biopsy is useful in predicting UIP pattern. <i>Respiratory Research</i> , <b>2012</b> , 13, 96	7.3	67
77	Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. <i>Journal of Translational Medicine</i> , <b>2012</b> , 10, 87	8.5	31
76	Predictive Role of Telomerase Activity in the Clinical Outcome of Patients with Benign Lesions of the Uterine Cervix or CIN. <i>Analytical Cellular Pathology</i> , <b>2012</b> , 35, 377-380	3.4	2
75	Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. <i>Tumori</i> , <b>2012</b> , 98, 696-701	1.7	12
74	FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy. <i>Journal of Cancer</i> , <b>2012</b> , 3, 241-5	4.5	27
73	Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma. <i>Technology in Cancer Research and Treatment</i> , <b>2012</b> , 11, 163-7	2.7	9
72	Reply to E. Schildmann et al. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4177-4178	2.2	5
71	Prospective comparison of prognostic scores in palliative care cancer populations. <i>Oncologist</i> , <b>2012</b> , 17, 446-54	5.7	96
70	Palliative sedation in end-of-life care and survival: a systematic review. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1378-83	2.2	216
69	Ipilimumab in advanced melanoma: reports of long-lasting responses. <i>Melanoma Research</i> , <b>2012</b> , 22, 263-70	3.3	39
68	Noninferiority trials in second-line treatments of nonsmall cell lung cancer: a systematic review of literature with meta-analysis of phase III randomized clinical trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2012</b> , 35, 593-9	2.7	4
67	Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. <i>Tumori</i> , <b>2012</b> , 98, 696-701	1.7	5

66	PP 39 Multi-determinants analysis of molecular alterations as predictor of resistance to cetuximab in metastatic colorectal cancer. <i>European Journal of Cancer</i> , <b>2011</b> , 47, S32-S33	7.5	
65	Bone metastases detection by circulating biomarkers: OPG and RANK-L. <i>International Journal of Oncology</i> , <b>2011</b> , 39, 255-61	4.4	9
64	Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. <i>Clinical Breast Cancer</i> , <b>2011</b> , 11, 369-75	3	45
63	Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 125, 775-84	4.4	17
62	Reproducibility of results on chronic pain with MC5-A Calmare <sup>®</sup> device from independent studies. <i>Supportive Care in Cancer</i> , <b>2011</b> , 19, 1685-6	3.9	
61	Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy. <i>Journal of Translational Medicine</i> , <b>2011</b> , 9, 94	8.5	11
60	Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome. <i>Melanoma Research</i> , <b>2011</b> , 21, 524-9	3.3	30
59	Erratum to "Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis" <i>Clinical and Developmental Immunology</i> , <b>2011</b> , 2011, 1-1		78
58	Survival prediction for terminally ill cancer patients: revision of the palliative prognostic score with incorporation of delirium. <i>Oncologist</i> , <b>2011</b> , 16, 1793-9	5.7	74
57	Liver metastases from melanoma: hepatic intra-arterial chemotherapy. A retrospective study. <i>Journal of Chemotherapy</i> , <b>2011</b> , 23, 300-5	2.3	13
56	The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study. <i>Oncology</i> , <b>2011</b> , 80, 225-31	3.6	17
55	Benefit from CMF with or without anthracyclines in relation to biologic profiles in early breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1031-1031	2.2	3
54	Expectations of survivors, caregivers and healthcare providers for testicular cancer survivorship and quality of life. <i>Tumori</i> , <b>2011</b> , 97, 367-73	1.7	9
53	GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer. <i>Hepato-Gastroenterology</i> , <b>2011</b> , 58, 599-603		7
52	Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2010</b> , 19, 2647-54	4	21
51	Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis. <i>Clinical and Developmental Immunology</i> , <b>2010</b> , 2010, 504979		17
50	The limit of therapies in oncology. <i>Journal of Medicine and the Person</i> , <b>2010</b> , 8, 112-120		2
49	Safety and efficacy of Scrambler therapy for cancer pain.. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e19591-e19591		

48	Transdermal Fentanyl as A Front-Line Approach to Moderate-Severe Pain: A meta-analysis of Randomized Clinical Trials. <i>Journal of Palliative Care</i> , <b>2009</b> , 25, 172-180	1.8	33
47	Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. <i>Chest</i> , <b>2009</b> , 135, 1596-1609	5.3	30
46	Palliative sedation therapy does not hasten death: results from a prospective multicenter study. <i>Annals of Oncology</i> , <b>2009</b> , 20, 1163-9	10.3	137
45	Quantitative fluorescence determination of long-fragment DNA in stool as a marker for the early detection of colorectal cancer. <i>Cellular Oncology</i> , <b>2009</b> , 31, 11-7		11
44	Controversial issues in thromboprophylaxis with low-molecular weight heparins in palliative care. <i>Journal of Pain and Symptom Management</i> , <b>2008</b> , 36, e3-4	4.8	6
43	Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. <i>Journal of Palliative Medicine</i> , <b>2008</b> , 11, 492-501	2.2	94
42	Serum free DNA and COX-2 mRNA expression in peripheral blood for lung cancer detection. <i>Thorax</i> , <b>2008</b> , 63, 843-4	7.3	18
41	Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis. <i>Breast Cancer Research and Treatment</i> , <b>2008</b> , 108, 259-64	4.4	9
40	Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations. <i>Breast Cancer Research and Treatment</i> , <b>2008</b> , 112, 343-9	4.4	6
39	Resection line involvement after gastric cancer surgery: clinical outcome in nonsurgically retreated patients. <i>World Journal of Surgery</i> , <b>2008</b> , 32, 2661-7	3.3	46
38	The palliative prognostic score and survival in patients with advanced solid tumors receiving chemotherapy. <i>Supportive Care in Cancer</i> , <b>2008</b> , 16, 359-70	3.9	38
37	A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. <i>Bone Marrow Transplantation</i> , <b>2006</b> , 38, 407-12	4.4	33
36	Impact of palliative care unit admission on symptom control evaluated by the edmonton symptom assessment system. <i>Journal of Pain and Symptom Management</i> , <b>2005</b> , 30, 367-73	4.8	67
35	A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. <i>Supportive Care in Cancer</i> , <b>2005</b> , 13, 888-94	3.9	86
34	Prognostic relevance of histological grade and its components in node-negative breast cancer patients. <i>Modern Pathology</i> , <b>2004</b> , 17, 1038-44	9.8	31
33	Lymph node micrometastases in early gastric cancer and their impact on prognosis. <i>World Journal of Surgery</i> , <b>2003</b> , 27, 558-61	3.3	66
32	HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 2708-12	2.2	41
31	Gastric cancer mortality in the spouses of patients who died from gastric cancer. <i>International Journal of Epidemiology</i> , <b>2002</b> , 31, 468-472	7.8	9

30	Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer. <i>International Journal of Cancer</i> , <b>2002</b> , 98, 228-33	7.5	35
29	Role of biological markers in the clinical outcome of colon cancer. <i>British Journal of Cancer</i> , <b>2002</b> , 87, 868-75	8.7	41
28	Gastric cancer mortality in the spouses of patients who died from gastric cancer. <i>International Journal of Epidemiology</i> , <b>2002</b> , 31, 468-472	7.8	5
27	High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. <i>Annals of Oncology</i> , <b>2001</b> , 12, 289-300	10.3	93
26	Lymph node micrometastases in patients with early gastric cancer: experience with 139 patients. <i>Annals of Surgical Oncology</i> , <b>2001</b> , 8, 170-4	3.1	36
25	Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen. <i>Breast Cancer Research and Treatment</i> , <b>2001</b> , 68, 101-10	4.4	6
24	A multicenter case-control study in Italy on hematolymphopoietic neoplasms and occupation. <i>Epidemiology</i> , <b>2001</b> , 12, 78-87	3.1	64
23	Lymph Node Micrometastases in Patients With Early Gastric Cancer: Experience With 139 Patients <b>2001</b> , 8, 170		1
22	Tumor microvessel density and prognosis in node-negative breast cancer. <i>International Journal of Cancer</i> , <b>2000</b> , 89, 74-80	7.5	35
21	Comparison between different cell kinetic variables in human breast cancer. <i>Cell Proliferation</i> , <b>2000</b> , 33, 75-89	7.9	13
20	Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study. <i>Breast Cancer Research and Treatment</i> , <b>2000</b> , 63, 181-92	4.4	47
19	The role of growth patterns, according to Kodama's classification, and lymph node status, as important prognostic factors in early gastric cancer: analysis of 412 cases. <i>Gastric Cancer</i> , <b>2000</b> , 3, 134-140	7.6	15
18	Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 3125-34	2.2	52
17	Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's Lymphoma?. <i>Leukemia and Lymphoma</i> , <b>2000</b> , 39, 301-10	1.9	41
16	Identification of occult micrometastases in patients with early gastric cancer using anti-cytokeratin monoclonal antibodies. <i>Oncology Reports</i> , <b>2000</b> , 7, 535-9	3.5	14
15	Tumor microvessel density and prognosis in node-negative breast cancer <b>2000</b> , 89, 74		2
14	A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. <i>Journal of Pain and Symptom Management</i> , <b>1999</b> , 17, 231-9	4.8	323
13	Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. <i>Journal of Pain and Symptom Management</i> , <b>1999</b> , 17, 240-7	4.8	303

12	Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer. <i>Lung Cancer</i> , <b>1999</b> , 24, 81-8	5.9	40
11	Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial. <i>Breast Cancer Research and Treatment</i> , <b>1998</b> , 49, 209-17	4.4	44
10	Multiple myeloma and work in agriculture: results of a case-control study in Forlì Italy. <i>Cancer Causes and Control</i> , <b>1998</b> , 9, 277-83	2.8	37
9	Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. <i>Journal of Pain and Symptom Management</i> , <b>1997</b> , 13, 1-9	4.8	93
8	Evaluation of the cost of home care for terminally ill cancer patients. <i>Supportive Care in Cancer</i> , <b>1997</b> , 5, 396-401	3.9	19
7	Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. <i>Supportive Care in Cancer</i> , <b>1997</b> , 5, 130-5	3.9	74
6	Gene amplification and proliferative kinetics in relation to prognosis of patients with gastric carcinoma. <i>Cancer</i> , <b>1997</b> , 79, 226-32	6.4	19
5	Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients <b>1997</b> , 5, 130		4
4	Studies signaling the prognostic factors of terminally ill phases. <i>Journal of Pain and Symptom Management</i> , <b>1996</b> , 12, 205	4.8	
3	Chronic lymphocytic leukaemias and non-Hodgkin's lymphomas by histological type in farming-animal breeding workers: a population case-control study based on a priori exposure matrices. <i>Occupational and Environmental Medicine</i> , <b>1996</b> , 53, 652-7	2.1	50
2	Chronic lymphocytic leukaemias and non-Hodgkin's lymphomas by histological type in farming-animal breeding workers: a population case-control study based on job titles. <i>Occupational and Environmental Medicine</i> , <b>1995</b> , 52, 374-9	2.1	44
1	Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. <i>Cancer</i> , <b>1995</b> , 75, 2613-22	6.4	170